Multicentre, double-blind, randomized, placebo-controlled, parallel-group, clinical trial to evaluates the clinical efficacy and safety of immunotherapy with purified major allergen Alt a 1 in patients with allergic rhinoconjunctivitis with or without mild to moderate asthma, sensitized the fungus Alternaria alternata [Ensayo clinico multicentrico, doble ciego, aleatorizado y controlado con placebo, en grupos paralelos, que evalua la eficacia clínica y seguridad de la inmunoterapia con el alergeno mayor purificado Alt a 1, en pacientes con rinoconjuntivitis alergica con o sin asma leve o moderada, sensibilizados al hongo Alternaria alternata]

Trial Profile

Multicentre, double-blind, randomized, placebo-controlled, parallel-group, clinical trial to evaluates the clinical efficacy and safety of immunotherapy with purified major allergen Alt a 1 in patients with allergic rhinoconjunctivitis with or without mild to moderate asthma, sensitized the fungus Alternaria alternata [Ensayo clinico multicentrico, doble ciego, aleatorizado y controlado con placebo, en grupos paralelos, que evalua la eficacia clínica y seguridad de la inmunoterapia con el alergeno mayor purificado Alt a 1, en pacientes con rinoconjuntivitis alergica con o sin asma leve o moderada, sensibilizados al hongo Alternaria alternata]

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Alternaria allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis; Hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2017 Status changed from recruiting to completed.
    • 04 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top